SYNERGY PHARMACEUTICALS LLC
SGYP evidence brief
What we can confirm
- BioSniper Score:
- 7.3 / 10
- Lead Asset:
- dolcanatide (Preclinical)
What it means
What to watch
Prepared research question
What matters most for SGYP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Market Cap
—
Cash Runway
—
Lead Asset
dolcanatide (Preclinical)
Next Catalyst
—
Tracking 2 pipeline candidates · 7 clinical trials for SYNERGY PHARMACEUTICALS LLC.
Run SYNERGY PHARMACEUTICALS LLC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available SYNERGY PHARMACEUTICALS LLC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Score breakdownBased on 2 of 6 signals · derived from public data
Cash runway data unavailable
Financial health data unavailable
Lead: Approved
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Frequently asked questions
What is SYNERGY PHARMACEUTICALS LLC's lead drug candidate?
SYNERGY PHARMACEUTICALS LLC's most advanced tracked candidate is dolcanatide (Preclinical) for GI diseases and disorders.
What therapeutic areas does SYNERGY PHARMACEUTICALS LLC focus on?
SYNERGY PHARMACEUTICALS LLC develops therapies across Oncology, Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.